CytoDyn (CYDY) Stock Price, News & Analysis

Company Overview

CytoDyn Inc. is a biotechnology company focused on the development of leronlimab, an investigational monoclonal antibody that targets CCR5, a receptor involved in immune-cell signaling and the movement of certain cells through the body. The company’s research has explored potential applications in infectious diseases, oncology and inflammatory conditions.

Leronlimab, also known as PRO 140, has been studied primarily as a potential treatment for HIV infection, including in combination with existing antiretroviral therapies. CytoDyn has also evaluated the drug in investigational programs involving cancer and other diseases. Leronlimab is not an approved product, and the company’s programs remain subject to clinical, regulatory and scientific development requirements.

CytoDyn is headquartered in Vancouver, Washington, and has historically operated as a development-stage biotechnology company rather than a commercial pharmaceutical business. The company’s activities have centered on clinical research, regulatory engagement and potential partnering related to leronlimab. Dr. Jacob Lalezari has served in a senior leadership role, including as chief executive officer, and has been associated with the company’s HIV development efforts.

Key Stats

• Today's Range: $0.20 to $0.20
• 50-Day Range: $0.19 to $0.25
• 52-Week Range: $0.18 to $0.40
• Volume: 1.62 million shs
• Average Volume: 1.50 million shs
• Market Capitalization: $303.55 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

CytoDyn Stock Analysis - MarketRank™

CytoDyn scored higher than 1% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for CytoDyn.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of CytoDyn is -10.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of CytoDyn is -10.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

2.54% of the float of CytoDyn has been sold short.

Short Interest Ratio / Days to Cover

CytoDyn has a short interest ratio ("days to cover") of 10.02, which indicates bearish sentiment.

Change versus previous month

Short interest in CytoDyn has recently decreased by 0.13%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

CytoDyn does not currently pay a dividend.

Dividend Growth

CytoDyn does not have a long track record of dividend growth.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

Search Interest

1 people have searched for CYDY on MarketBeat in the last 30 days.

MarketBeat Follows

Only 1 people have added CytoDyn to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

Company Ownership

• Score: 0.1 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, CytoDyn insiders have not sold or bought any company stock.

Percentage Held by Insiders

1.00% of the stock of CytoDyn is held by insiders.

Percentage Held by Institutions

5.06% of the stock of CytoDyn is held by institutions.

Company Calendar

• Last Earnings: 1/09/2026
• Today: 10/08/2026
• Next Earnings (Estimated): 10/08/2026
• Fiscal Year End: 5/31/2027

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: OTCMKTS:CYDY
• Previous Symbol: NASDAQ:CYDY
• CIK: 1175680
• Web: www.cytodyn.com
• Phone: (360) 980-8524
• Fax: N/A
• Employees: 14
• Year Founded: 2002

Profitability

• EPS (Trailing Twelve Months): ($0.02)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$42.70 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: -190.29%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.26
• Quick Ratio: 0.26

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.08) per share
• Price / Book: -2.50

Miscellaneous

• Outstanding Shares: 1,518,520,000
• Free Float: 1,454,823,000
• Market Cap: $303.55 million
• Optionable: Not Optionable
• Beta: 1.50